A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases

Inclusion Criteria: * Providing a written informed consent (see Appendix A); * Age ≥18 years; * Histologic or cytologic confirmed diagnosis of NSCLC of any epithelial type (squamous, adenocarcinoma, large cell, or other); * At least one newly diagnosed measurable metastatic lesion from NSCLC in the brain; * Patient had initial diagnosis of brain metastases by image, within 8 weeks of registration * KPS ≥70; * Absolute neutrophil count ≥ 1500/mm³; * Platelet count ≥ 50,000/mm³; * Serum creatinine ≤2.0 mg/dL; * Serum transaminases ≤2 x the upper limit of normal (ULN); * Total serum bilirubin ≤2 x ULN; * And a lactate dehydrogenase (LDH) level ≤1.3 x ULN. Exclusion Criteria: * Pregnancy, lactation or parturition within the previous 30 days (fertile female or male patients should practice contraception); * Prior WBRT, brain metastases resection with no other measurable lesion remaining; * Extracranial metastases in two or more organs; * Known leptomeningeal or subarachnoid tumor spread; * Plan to use radiosurgery or radiation boost after completion of WBRT; * Plan to use chemotherapy or any other systemic antineoplastic modality during WBRT; * Previous use of an anti-EGFR drug; * Participation in another ongoing therapeutic trial; * Presence of known HIV seropositivity, severe comorbidities, or other malignant neoplasm within 5 years (except adequately treated basal- or squamous-cell carcinoma of skin or in situ carcinoma of the uterine cervix); * Hypersensitivity or allergy to any of the drugs to be administered in this study; * Inability or unwillingness to complete the required assessments; * Geographic inaccessibility for treatment or follow-up evaluations.